Engraftment of dopamine neuron precursor cells derived from adult mesenchymal stem cells: preliminary in vivo study

Abstract

The use of stem cells has been proposed as an alternative treatment for certain neurodegenerative disorders. It has also been suggested that pre-differentiated stem cells might provide a better therapeutic option than differentiated or undifferentiated stem cells.

The aim of this preliminary study was to determine if immature dopamine neurons cells are capable to engraf into a Parkinson’s Disease rat model. Stem cells from rat bone marrow, undifferentiated or pre-differentiated into dopamine precursor cells were implanted into brains of rats Parkinson Disease model. Histological brain analysis and rat rotational behavior were analyzed 1 and 2 weeks after transplantation. Immuno-histochemical analysis of brains showed positive engraftment of transplanted and survived at last for 3 weeks after transplantation. Rotational behavior showed a significantly decreased (P<0.05) on rats transplanted with pre-differentiated cells. We present preliminary evidence that dopamine precursor neurons could be an option for Parkinson’s Disease cell therapy.

Keywords: dopamine precursor cells, neuro-differentiation, parkinson’s disease, mesenchymal stem cells

Abbreviations: PD, parkinson’s diseases; iPSCs, induced pluripotent stem cells; ESCs, embryonic stem cells; MSCs, mesenchymal stem cells; BrdU, bromodeoxyuridine; 6-OHDA, 6-hydroxy-dopamine; MFB, medial forebrain bundle

Introduction

Cell therapy has been proposed as an alternative for treatment of neurodegenerative disorder. Parkinson’s Diseases (PD) are caused by specific and selective loss of nigrostriatal dopaminergic neurons.1 The possibility of replacing those cells has been explored through the transplantation of embryonic stem cells (ESCs), fetal stem cells, induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs) in animal models and clinical trials.1,2 The aim of this study was to explore the possibility of transplanting adult MSCs pre-differentiated into dopaminergic neurons and look for their capability to brain engrafment and the possible improvement of PD symptoms in a PD rat model.

MSCs were obtained from bone marrow femurs adult male Wistar rats were culture with DMEM medium or Neuro-induction medium3 (Figure 1). Undifferentiated and dopamine neuron precursor cells were labeled with bromodeoxyuridine (BrdU) (Sigma-Aldrich, St. Louis, MO). For PD model, animals were unilaterally injected with 6-hydroxydopamine (6-OHDA) (16µg/2.5µL dissolved in ascorbate-saline; Sigma-Aldrich) into the right medial forebrain bundle (MFB) with stereotaxis.4,5 On this pilot research, three weeks after the 6-OHDA lesion, the rats were divided into two groups. One group (n=2) was transplanted with 1X10^5 undifferentiated MSCs suspended in 2.5µL PBS. The second group (n=3) was transplanted with 1X10^5 dopamine neuron precursor cells suspended in 2.5µL PBS. Cells were transplanted to the same area of the previous 6-OHDA injection. The coordinates of the injections were AP-1.8; ML 1.5 DV 7.3mm (Figure 2).

Rotational behavior

To determine any possible beneficial effect of undifferentiated or dopamine neuron precursor cells transplantation, rotational behavior was determined at 1 and 2 weeks after transplantation by intraperitoneal injection of 0.5mg/kg apomorphine in 0.9% ascorbic acid solution6 (Sigma-Aldrich). The number of rotations made by each rat was counted for 90 min, beginning 10 min after the injection. Differences in number of rotations between groups were analyzed by the T-student test.
Engraftment of dopamine neuron precursor cells derived from adult mesenchymal stem cells: preliminary in vivo study

Results

Immunodetection of MSCs transplanted into rat brains: Three weeks after cell transplantation into the brain, rats were sacrificed and the brains were obtained for immunohistological analysis. Results confirmed cell engraftment in the brain at the MFB, without migration of the transplanted cells to different areas (Figure 3).

Apopomorphine-induced rotational behavior: Rat rotational behavior was determined 4 and 5 weeks after the induction of a Parkinsonian lesion by means of a 6-OHDA injection. After 1 and 2 weeks post-transplantation, animals transplanted with dopamine neuron precursor cells showed a significant decrease in rotational behavior with respect to the baseline (P<0.05), but no significant decrease in rotational behavior was observed in rats transplanted with undifferentiated MSCs (Figure 4).

Discussion

Transplantation of neural cell aggregates as well as dopaminergic neurons derived from embryonic stem cells in PD animal models have proved to possess potential in improving behavioral tests and cell grafting. However obtaining of human brain neural stem cells for transplantation may limit this procedure as potential therapy. Additionally, the use of embryonic stem cells faces ethical concerns with limitation for their use. Bone marrow mesenchymal stem cell, also has demonstrated to prevent neuronal damage in a PD animal model, suggesting its potential use as early stage PD therapy.

In this preliminary research the use of neuronal precursor, demonstrate that these cells are capable of engrafting into brain tissue and increased capability of improving behavioral tests compared with bone marrow stem cells alone. In addition the use of dopamine neuron precursor cells obtained in short time periods reduces contamination probabilities, and epigenetic changes. In order to obtain more conclusive evidence, it will be necessary increase the number of animals in the experimental groups.

Conclusion

The feasibility of cell isolation (Autologous bone marrow) and harvest (using a single-step pre-differentiation media), along with this
preliminary results obtained in the animal model, provides evidence of the probable potential of this procedure as therapy for PD. Further studies conducted with longer follow-up will set the guideline to design clinical studies.

**Acknowledgements**

The authors express their appreciation to Janet Gutierrez-Alcala and Rosa Maria de la Rosa for technical assistance.

**Funding**

This work was partially funded by endowments from ITESM (cat-134) and the Zambrano-Hellion Foundation.

**Author disclosure statement**

None of the authors has any commercial relationship with any pharmaceutical or biotechnological company. The authors declare that no competing interests exist.

**Conflict of interest**

The author declares no conflict of interest.

**References**

1. Behari M, Singhal KK. Cell based therapies in Parkinson’s Disease. *Ann Neurosci*. 2011;18(2):76–83.

2. Lescaudron L, Boyer C, Bonnamain V, et al. Assessing the potential clinical utility of transplantations of neural and mesenchymal stem cells for treating neurodegenerative diseases. *Methods Mol Biol*. 2012;879:147–164.

3. Zavala–Arcos J, Gonzalez–Garza MT, Gutierrez–Alcala J, et al. Direct pre–differentiation of rat mesenchymal stem cells into dopaminergic cells. *Stem cell Dis*. 2013;3(2):133–138.

4. Smith MP, Cass WA. Oxidative stress and dopamine depletion in an intrastriatal 6–hydroxydopamine model of Parkinson’s disease. *Neuroscience*. 2007;144(3):1057–1066.

5. Kelsey JE, MagueSD, PijanowskiRS, et al. NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6–OHDA in rats. *Psychopharmacology*. 2004;175(2):179–188.

6. Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. *J Pharmacol Exp Ther*. 2002;303(2):791–804.

7. Shin ES, Hwang O, Hwang YS, et al. Enhanced efficacy of human brain–derived neural stem cells by transplantation of cell aggregates in a rat model of Parkinson’s disease. *J Korean Neurosurg Soc*. 2014;56(5):383–389.

8. Peng J, Liu Q, Rao MS, et al. Survival and engraftment of dopaminergic neurons manufactured by a Good Manufacturing Practice–compatible process. *Cytotherapy*. 2014;16(9):1305–1312.

9. Capitelli CS, Lopes CS, Alves AC, et al. Opposite effects of bone marrow–derived cells transplantation in MPTP–rat model of Parkinson’s disease: a comparison study of mononuclear and mesenchymal stem cells. *Int J Med Sci*. 2014;11(10):1049–1064.

10. Suzuki S, Kawamata J, Iwahara N, et al. Intravenous mesenchymal stem cell administration exhibits therapeutic effects against 6–hydroxydopamine–induced dopaminergic neurodegeneration and glial activation in rats. *Neurosci Lett*. 2015;584:276–281.